Purpose Some previously published primarily retrospective studies have shown that statins could reduce the rate and severity of exacerbations, the length of hospital stays, and mortality in patients with chronic obstructive pulmonary disease (COPD), but retrospective data needs to be reviewed regarding this connection since statins are cholesterol-lowering drugs. Therefore, the aim of this study was to investigate the independent influence of statins on the exacerbation rate in COPD patients. Methods An observational retrospective study was conducted to assess the independent influence of statins on the COPD exacerbation rate at the Department of Internal Medicine, Pulmonary Division, Internal Intensive Care Medicine, Infectiology, and Sleep Medicine, Märkische Clinics Health Holding Ltd, Clinic Lüdenscheid, Witten/Herdecke University from January 1, 2010 to December 31, 2020. This study enrolled patients with COPD in 2010 and documented their exacerbation rate over a further 10 years. The number of exacerbations in COPD patients was compared between statin users and non-users. Results Of the total of 295 [176 male (59.7%)] COPD patients, 105 (35.6%, CI 30.3–41.2%) patients with COPD were treated with statins, and 190 (64.4%, CI 58.8–69.7%) were treated without statins. The mean exacerbation rate in the COPD patients who received statin did not differ from that in the COPD patients who did not receive statin ( p = 0.175). Also, the mortality rates did not differ between the statin-treated and non-statin-treated COPD patients ( p = 0.271). Conclusion Statins have no effect on the exacerbation rate or mortality in COPD patients.
Die High-Flow-Sauerstofftherapie (HFOT) ist bei der Behandlung von Patienten mit hypoxämischer Ateminsuffizienz und hohem Sauerstoffbedarf eine bewährte Alternative zur konventionellen O 2-Therapie über eine Nasenbrille oder Maske. Prinzipkurz zusammengefasst Die nasale High-Flow-Therapie (NHF) appliziert über eine großlumige Sauerstoffnasenbrille hohe Flussmengen angefeuchteter und erwärmter Luft in die Atemwege. Dabei gibt das NHF-Gerät reinen Sauerstoff oder ein frei dosierbares Sauerstoff-Luft-Gemisch ab. Aus der optimierten Atemgaskonditionierung und dem Atemgasfluss (Flow) resultieren im Wesentlichen 3 Effekte auf die Atmung, die in der Summe die Atemarbeit reduzieren [2]: ▪ Verbesserte Oxygenierung. ▪ Auswaschung des physiologischen Totraums der oberen Atemwege. ▪ Die verbesserte mukoziliäre Clearance erleichtert die Sekretmobilisation und reduziert so den Atemwegswiderstand. Merke Die nasale High-Flow-Therapie beeinflusst ventilatorische Parameter, Dyspnoe und senkt die Atemarbeit [3]. Einstellgrößen der NHF sind Atemgastemperatur, Atemgasfluss und Sauerstoffgehalt. Durch Erwärmen und Anfeuchten des Atemgases tolerieren die Patienten die hohen Flussraten sehr gut. Dieses Dokument wurde zum persönlichen Gebrauch heruntergeladen. Vervielfältigung nur mit Zustimmung des Verlages.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.